Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$1.97 - $2.97 $94,057 - $141,802
-47,745 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$2.56 - $5.25 $122,227 - $250,661
47,745 New
47,745 $123,000

Others Institutions Holding BLRX

About BioLineRx Ltd.


  • Ticker BLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,524,500
  • Market Cap $36.9M
  • Description
  • BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...
More about BLRX
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.